المؤلفون: E. A. Polyanskaya, Е. А. Полянская

المساهمون: исследование проведено без использования спонсорской поддержки

المصدر: Translational Medicine; Том 10, № 2 (2023); 116-122 ; Трансляционная медицина; Том 10, № 2 (2023); 116-122 ; 2410-5155 ; 2311-4495

مصطلحات موضوعية: персистирующая форма фибрилляции предсердий, hospitalization, lethal outcome, permanent atrial fibrillation, persistent atrial fibrillation, unfavorable prognosis, кардиоренальный синдром, летальный исход, неблагоприятный прогноз, перманентная форма фибрилляции предсердий

وصف الملف: application/pdf

العلاقة: https://transmed.almazovcentre.ru/jour/article/view/813/508Test; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/813/1809Test; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/813/1810Test; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/813/1811Test; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/813/1829Test; Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019; 139(10):e56–e528. DOI:10.1161/CIR.0000000000000659.; Zafrir B, Lund LH, Laroche C, et al. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J. 2018; 39(48):4277–4284. DOI:10.1093/eurheartj/ehy626.; Bansal N, Xie D, Tao K, et al. Atrial Fibrillation and Risk of ESRD in Adults with CKD. Clin J Am Soc Nephrol. 2016; 11(7):1189–1196. DOI:10.2215/CJN.10921015.; Chen TH, Chu YC, Ou SM, et al. Associations of atrial fibrillation with renal function decline in patients with chronic kidney disease. Heart. 2022; 108(6):438–444. DOI:10.1136/heartjnl-2021-319297.; Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation. 2019; 139(16):e840–e878. DOI:10.1161/CIR.0000000000000664.; Мухин Н.А., Глыбочко П.В., Свистунов А.А. и др. Хроническая болезнь почек и фибрилляция предсердий как компоненты кардиоренального континуума. Терапевтический архив. 2016; 88(6):4–8]. DOI:10.17116/terarkh20168864-8.; Hanna-Rivero N, Tu SJ, Elliott AD, et al. Anemia and iron deficiency in patients with atrial fibrillation. BMC Cardiovasc Disord. 2022; 22(1):204. DOI:10.1186/s12872022-02633-6.; Alnuwaysir RIS, Grote Beverborg N, Hoes MF, et al. Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the BIOSTAT-CHF study. Eur J Heart Fail. 2022; 24(1):192–204. DOI:10.1002/ejhf.2393.; Hao C, Luo J, Liu B, et al. Prognostic Significance of New-Onset Atrial Fibrillation in Heart Failure with Preserved, Mid-Range, and Reduced Ejection Fraction Following Acute Myocardial Infarction: Data from the NOAFCAMI-SH Registry. Clin Interv Aging. 2022; 17:479–493. DOI:10.2147/CIA.S358349.; Kolben Y, Kessler A, Puris G, et al. Management of heart failure with reduced ejection fraction: challenges in patients with atrial fibrillation, renal disease and in the elderly. Rev Cardiovasc Med. 2022; 23(1):16. DOI:10.31083/j.rcm2301016.; Жиров И.В., Сафронова Н.В., Осмоловская Ю.Ф. и др. Прогностическое значение фибрилляции предсердий у пациентов с сердечной недостаточностью с разной фракцией выброса левого желудочка: результаты многоцентрового регистра РИФ-ХСН. Российский кардиологический журнал. 2021; 26(1):4200]. DOI:10.15829/1560-40712021-4200.; Sartipy U, Dahlström U, Fu M, et al. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. JACC Heart Fail. 2017; 5(8):565–574. DOI:10.1016/j.jchf.2017.05.001.; Ардашев А.В., Беленков Ю.Н., Матюкевич М.Ч. и др. Фибрилляция предсердий и смертность: прогностические факторы и терапевтические стратегии. Кардиология. 2021; 61(2):91–98]. DOI:10.18087/cardio.2021.2.n1348.; Heijman J, Luermans JGLM, Linz D, et al. Risk Factors for Atrial Fibrillation Progression. Card Electrophysiol Clin. 2021;13(1):201–209. DOI:10.1016/j.ccep.2020.10.011.; https://transmed.almazovcentre.ru/jour/article/view/813Test

الإتاحة: https://doi.org/10.18705/2311-4495-2023-10-2-116-122Test
https://doi.org/10.1161/CIR.0000000000000659Test
https://doi.org/10.1093/eurheartj/ehy626Test
https://doi.org/10.2215/CJN.10921015Test
https://doi.org/10.1136/heartjnl-2021-319297Test
https://doi.org/10.1161/CIR.0000000000000664Test
https://doi.org/10.17116/terarkh20168864-8Test
https://doi.org/10.1186/s12872022-02633-6Test
https://doi.org/10.1002/ejhf.2393Test
https://doi.org/10.2147/CIA.S358349Test

المؤلفون: E. A. Polyanskaya, M. Yu. Fedyanin, A. A. Tryakin, S. A. Tjulandin, Е. А. Полянская, М. Ю. Федянин, А. А. Трякин, С. А. Тюляндин

المصدر: Pelvic Surgery and Oncology; Том 8, № 4 (2018); 11-29 ; Тазовая хирургия и онкология; Том 8, № 4 (2018); 11-29 ; 2686-7435 ; 10.17650/2220-3478-2018-8-4

مصطلحات موضوعية: анализ кала на скрытую кровь, screening, colonoscopy, fecal occult blood test, скрининг, колоноскопия

وصف الملف: application/pdf

العلاقة: https://ok.abvpress.ru/jour/article/view/263/223Test; Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBO-CAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394—424. PMID: 30207593. DOI:10.3322/caac.21492.; Приказ Министерства здравоохранения РФ от 26 октября 2017 г. № 869н «Об утверждении порядка проведения диспансеризации определенных групп взрослого населения».; Labianca R., Nordlinger B., Beretta G.D. et al. Clinical practice guidelines Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6): vi64-72. PMID: 24078664. DOI:10.1093/annonc/mdt354.; GGPO. Evidenced-based Guideline for Colorectal Cancer, long version 1.0. Berlin, 2014. Available at: http://www.awmf.org/ffleadmin/user_upload/Leitlinien/021_D_Ges_fuer_Verdau-ungs-_und_StoffwechseLkrankheit-en/021-007_S3_Colorectal_Cancer_2015_03-extended.pdfTest.; Bacchus C.M., Dunfield L., Gorber S.C. et al. Recommendations on screening for colorectal cancer in primary care. CMAJ 2016;188(5):340—8. PMID: 26903355. DOI:10.1503/cmaj.151125.; National Comprehensive Cancer Network Guidelines, version 2.2017. Colorectal Cancer Screening. Available at: https://www.nccn.org/professionals/physician_gls/default.aspxTest.; Bibbins-Domingo K., Grossman D.C., Curry S.J. et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2016;315(23):2564—75. PMID: 27304597. DOI:10.1001/jama.2016.5989.; Guerra C.E., LaMonte S.J., Etzioni R. et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin 2018;68(4):250-81. DOI:10.3322/caac.21457.; Rex D.K., Boland C.R., Domonitz J.A. et al. Colorectal Cancer Screening Recommendations for physicians and patients from the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2017;112(7):1016—30. DOI:10.1038/ajg.2017.174.; Sung J.J., Ng S.C., Chan F.K. et al. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut 2015;64(1):121—32. PMID: 24647008. DOI:10.1136/gutjnl-2013-306503.; Fang J.Y., Zheng S., Jiang B. et al. Consensus on the Prevention, Screening, Early Diagnosis and Treatment of Colorectal Tumors in China: Chinese Society of Gastroenterology. Gastrointest Tumors 2014;1(2):53—75. PMID: 26672726. DOI:10.1159/000362585.; Hamzehzadeh L., Yousefi M., Ghaffari S.H. Colorectal cancer screening: a comprehensive review to recent non-invazive methods. Int J Hematol Oncol Stem Cell Res 2017;11(3):250—61. PMID: 28989593.; Davies R.J., Miller R., Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer 2005;5(3):199—209. PMID: 15738983. DOI:10.1038/nrc1545.; Hassan C., Giorgi Rossi P., Camilloni L. et al. Metaanalysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther 2012;36(10):929—40. PMID: 23035890. DOI:10.1111/apt.12071.; Telford J.J., Levy A.R., Sambrook J.C. et al. The cost-effectiveness of screening for colorectal cancer. CMAJ 2010;182(12):1307—13. PMID: 20624866. DOI:10.1503/cmaj.090845.; Cooper G.S., Kou T.D., Rex D.K. Complications following colonoscopy with anesthesia assistance: a population-based analysis. JAMA Intern Med 2013;173(7):551—6. PMID: 23478904. DOI:10.1001/jamainternmed.2013.2908.; Fitzpatrick-Lewis D., Ali M.U., Warren R. et al. Screening for Colorectal Cancer: A Systematic Review and Meta-Analysis Clinical Colorectal Cancer. Clin Colorectal Cancer 2016;15(4):298-313. DOI:10.1016/j.clcc.2016.03.003.; Schoen R.E., Machicado J.D. Detection of advanced neoplasia with FIT versus flexible sigmoidoscopy versus colonoscopy: more is more. Dig Dis Sci 2015;60(5):1123— 5. PMID: 25701322. DOI:10.1007/s10620-015-3583-2.; Holme O., Loberg M., Kalager M. et al. Long-term effectiveness of sigmoidoscopy screening on colorectal cancer incidence and mortality in women and men: a randomized trial. Ann Intern Med 2018;168(11):775—82. DOI:10.7326/M17-1441.; Rockey D.C., Paulson E., Niedzwiecki D. et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet 2005;365(9456):305—11. PMID: 15664225. DOI:10.1016/S0140-6736(05)17784-8.; Van Gossum A., Munoz-Navas M., Fernandez-Urien I. et al. Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N Engl J Med 2009;361(3):264—70. PMID: 19605831. DOI:10.1056/NEJMoa0806347.; Eliakim R., Yassin K., Niv Y. et al. Prospective multicenter performance evaluation of the second-generation colon capsule compared with colonoscopy. Endoscopy 2009;41(12):1026-31. PMID: 19967618. DOI:10.1055/s-0029-1215360.; Goede S.L., Rabeneck L., BaUegooijen M. et al. Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening. PLoS One 2017;12(3):e0172864. DOI:10.1371/journal.pone.0172864.; Allison J.E., Tekawa I.S., Ransom L.J., Adrain A.L. A comparison of fecal occultblood tests for colorectal-cancer screening. N Engl J Med 1996;334(3):155-9. PMID: 8531970. DOI:10.1056/NEJM199601183340304.; Lieberman D. Colon cancer screening and surveillance controversies. Curr Opin Gastroenterol 2009;25(5):422-7. PMID: 19465849. DOI:10.1097/MOG.0b013e32832d1e2a.; Ahlquist D.A., Klee G.G., McGill D.B., Ellesfon R.D. Colorectal cancer detection in the practice setting. Impact of fecal blood testing. Arch Intern Med 1990;150(5):1041—5. PMID: 2331185.; Vm Dam L., Kuipers E.J., van Leerdam M.E. Performance improvements of stool-based screening tests. Best Pract Res Clin Gastroenterol 2010;24(4):479-92. PMID: 20833351. DOI:10.1016/j.bpg.2010.03.009.; Li S., Wang H., Hu J. et al. New immunochemical fecal occult blood test with two-consecutive stool sample testing is a cost-effective approach for colon cancer screening: results of a prospective multicenter study in Chinese patients. Int J Cancer 2006;118(12):3078-83. PMID: 16425283. DOI:10.1002/ijc.21774.; Toth K., Sipos F., Kalmar A. et al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS One 2012;7(9):e46000. PMID: 23049919. DOI:10.1371/journal.pone.0046000.; Steele R.J., McClements P., Watling C. et al. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. Gut 2012;61(4):576—81. PMID: 21930729. DOI:10.1136/gutjnl-2011-300535.; Brenner H., Haug U., Hundt S. Sex differences in performance of fecal occult blood testing. Am J Gastroenterol 2010;105(11):2457—64. PMID: 20700114. DOI:10.1038/ajg.2010.301.; Van Rossum L.G., van Rijn A.F., Laheij R.J. et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008;135(1):82— 90. PMID: 18482589. DOI:10.1053/j.gastro.2008.03.040.; Ahlquist D.A., Sargent D.J., Loprinzi C.L. et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008;149(7):441 — 50. PMID: 18838724.; Pignone M., Campbell M.K., Carr C., Phillips C. Meta-analysis of dietary re-striction during fecal occult blood testing. Eff Clin Pract 2001;4(4):150—6. PMID: 11525101.; Rozen P., Levi Z., Hazai R. et al. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms. Aliment Pharmacol Ther 2009;29(4):450-7. PMID: 19035980. DOI:10.1111/j.1365-2036.2008.03898.x.; Parra-Blanco A., Gimeno-Garcia A.Z., Quintero E. et al. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. J Gastroenterol 2010;45(7):703—12. PMID: 20157748. DOI:10.1007/s00535-010-0214-8.; Park D.I., Ryu S., Kim Y.H. et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk under-going colorectal cancer screening. Am J Gastroenterol 2010;105(9):2017—25. PMID: 20502450. DOI:10.1038/ajg.2010.179.; Dickinson B.T., Kisiel J., Ahlquist D.A., Grady W.M. Molecular markers for colorectal cancer screening. Gut 2015;64(9):1485—94. PMID: 25994221. DOI:10.1136/gutjnl-2014-308075.; Shapiro J.A., Bobo J.K., Church T.R. et al. A comparison of fecal immunochemical and high-sensitivity guaiac tests for colorectal cancer screening. Am J Gastroenterol 2017;112(11):1728—35. PMID: 29016558. DOI:10.1038/ajg.2017.285.; Asteria C.R., Pucciarelli S., Gerard L. et al. The impact of colorectal screening program on the detection of right-sided colorectal cancer. A 5-year cohort study in the Mantua District. Int J Colorectal Dis 2015;30(12):1627—37. PMID: 26255258. DOI:10.1007/s00384-015-2352-1.; Guittet L., Bouvier V., Mariotte N. et al. Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population ac-cording to positivity threshold and number of samples. Int J Cancer 2009;125(5):1127—33. PMID: 19431212. DOI:10.1002/ijc.24407.; Chambers JA, Callander A.S., Grangeret R., O’Carroll R.E. Attitudes towards the Faecal Occult Blood Test (FOBT) versus the Faecal Immunochemical Test (FIT) for colorectal cancer screening: perceived ease of completion and disgust. BMC Cancer 2016;16:96. PMID: 26872450. DOI:10.1186/s12885-016-2133-4.; Denters M.J., Deutekom M., Bossuyt P.M. et al. A feces collection paper does not enhance participation in a fecal immunochemical test-based colorectal cancer screening program: randomized clinical trial. Eur J Cancer Prev 2013;22(4):299— 304. PMID: 23169243. DOI:10.1097/CEJ.0b013e32835b3882.; Church T.R., Wandell M., Lofton-Day C. et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014;63(2):317—25. PMID: 23408352. DOI:10.1136/gutjnl-2012-304149.; Михайлова Е.И., Шуляк Ж.В. Прогнозирование нозологической формы наиболее распространённой органической патологии кишечника на основе фекального лактоферрина и иммуно-химического теста на скрытую кровь в кале. Колопроктология 2015;1(51):127—8.; Михайлова Е.И., Филипенко Н.В. Диагностическая значимость фекального лактоферрина и гваяковой пробы в выявлении колоректального рака. Колопроктология 2011;3(37):90—1.; Ned R.M., Melillo S., Marrone M. Fecal DNA testing for colorectal cancer screening: The colosure test. PLoS Curr 2011;3:RRN1220. DOI:10.1371/currents.RRN1220.; Ahlquist DA., Taylor WR., Mahoney D.W et al. The stool DNA test is more accurate than the plasma septin 9 Test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol 2012;10(3):272—7. PMID: 22019796. DOI:10.1016/j.cgh.2011.10.008.; Imperiale T.F., Ransohoff D.E., Itzkowitz S.H. et al. Fecal DNA vs. fecal occult blood for colorectal cancer screening in an average-risk population. N Engl J Med 2004;351(26):2704—14. PMID: 15616205. DOI:10.1056/NEJ-Moa033403.; Imperiale T.F., Ransohoff D.E., Itzkowitz S.H. et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370(14):1287—97. PMID: 24645800. DOI:10.1056/NEJ-Moa1311194.; Berger B.M., Schroy P.C., Dinh T.A. Screening for colorectal cancer using a multitarget stool DNA test: modeling the effect of the intertest interval on clinical effectiveness. Clin Colorectal Cancer 2016;15(3):e65—74. DOI:10.1016/j.clcc.2015.12.003.; Itzkowitz S.H., Brand R., Jandorf L. et al. A simplified, non-invasive stool DNA test for colorectal cancer detection. Am J Gastroenterol 2008;103(11):2862—70. PMID: 18759824. DOI:10.1111/j.1572-0241.2008.02088.x.; Boynton K.A., Summerhayes I.C., Ahlquist D.A., Shuber A.P. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 2003;49(7):1058—65. PMID: 12816901.; Бутрович Г.М., Мирлина Е.Д., Грозов Р.В. и др. ПЦР-анализ фекальной ДНК для скрининга колоректального рака. Ученые записки СПбГМУ им. акад. И.П. Павлова 2014;21(4):58—9.; Kopreski M.S., Benko F.A., Borys D.J. et al. Somatic mutation screening: identi-fication of individuals harboring KRAS mutations with the use of plasma DNA. J Natl Cancer Inst 2000;92(11):918-23. PMID: 10841827.; Tsai W.-S., Nimgaonkar A., Segurado O. et al. Prospective clinical study of circulating tumor cells for colorectal cancer screening. J Clin Oncol 2018;36(Suppl 4S):abstr 556. DOI:10.1200/JCO.2018.36.4_suppl.556.; Pickhardt PJ., Hassan C., Halligan S., Marmo R. Colorectal cancer: CT colonography and colonoscopy for detection-systematic review and meta-analysis. Radiology 2011;259(2):393—405. PMID: 21415247. DOI:10.1148/radiol.11101887.; Johnson C.D., Chen M-H., Toledano A.Y. et al. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 2008;359(12):1207—17. PMID: 18799557. DOI:10.1056/NEJ-Moa0800996.; De Haan M.C., van Gelder R.E., Graser A. et al. Diagnostic value of CT-colonography as compared to colonoscopy in an asymptomatic screening population: a metaanalysis. Eur Radiol 2011;21(8):1747—63. PMID: 21455818. DOI:10.1007/s00330-011-2104-8.; Ristvedt S.L., McFarland E.G., Weinstock L.B., Thyssen E.P. Patient preferences for CT colonography, conventional colonoscopy, and bowel preparation. Am J Gastroenterol 2003;98(3):578—85. PMID: 12650790.; https://ok.abvpress.ru/jour/article/view/263Test

الإتاحة: https://doi.org/10.17650/2220-3478-2018-8-4-11-29Test
https://doi.org/10.17650/2220-3478-2018-8-4Test
https://doi.org/10.3322/caac.21492Test
https://doi.org/10.1093/annonc/mdt354Test
https://doi.org/10.1503/cmaj.151125Test
https://doi.org/10.1001/jama.2016.5989Test
https://doi.org/10.3322/caac.21457Test
https://doi.org/10.1038/ajg.2017.174Test
https://doi.org/10.1136/gutjnl-2013-306503Test
https://doi.org/10.1159/000362585Test